Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Denali Therapeutics Inc. (NASDAQ: DNLI).

Full DD Report for DNLI

You must become a subscriber to view this report.


Recent News from (NASDAQ: DNLI)

Denali's Transport Vehicle Platform Holds Hidden Value In Brain Cancers
The passing of an American hero highlights a blindspot in cancer research Sen. McCain in attendance of a baseball game last year in Phoenix. Source Senator John McCain, prisoner of war, torture survivor and longtime civil servant, has passed away following a battle with an aggressiv...
Source: SeekingAlpha
Date: August, 29 2018 07:13
Denali Therapeutics misses by $0.39, misses on revenue
Denali Therapeutics (NASDAQ: DNLI ): Q2 EPS of -$0.59 misses by $0.39 . More news on: Denali Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 09 2018 17:00
Denali Therapeutics Reports Second Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2018. ...
Source: GlobeNewswire
Date: August, 09 2018 16:30
Denali Therapeutics Appoints Dana Andersen, Ph.D., as Chief Technical and Manufacturing Officer
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that Dr. Dana Andersen has joined the company as Chief Techn...
Source: GlobeNewswire
Date: August, 07 2018 16:30
Your Daily Pharma Scoop: Theravance Positive, Denali Encouraging, Redhill Clarifies Data
Stocks in News: TBPH, DNLI Theravance's TD-9855 shows positive effect in low blood pressure disorder study Theravance Biopharma ( TBPH ) reported positive data of a four-week data from a Phase 2 clinical trial of TD-9855. The candidate is an once-daily norepinephrine and serotonin reup...
Source: SeekingAlpha
Date: August, 03 2018 00:56
Biotech Analysis Central Pharma News: Teva's U.S. Erosion, Denali's Preliminary Results, Epizyme's Trial Shutdown
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Teva Dips As U.S. Generic Sales Continue To Drop News: Recently, Teva Pharmaceuticals ( TEVA ) announced its Q2 earnings. It reported adjusted inco...
Source: SeekingAlpha
Date: August, 03 2018 00:16
After Hours Gainers / Losers (08/01/2018)
Top Gainers: DXCM +19.5% . ESIO   +16.6%.   RUBI   +15.1% .  HABT +11.6% . DNLI +10.4% . More news on: DexCom, Inc., Electro Scientific Industries, Inc., The Rubicon Project, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 01 2018 17:35
Denali's DNL201 shows encouraging action in early-stage study; shares ahead 11% after hours
Denali Therapeutics (NASDAQ: DNLI ) is up  11%  after hours on light volume on the heels of its announcement of positive data from a Phase 1 clinical trial evaluating Parkinson's candidate DNL201. More news on: Denali Therapeutics, Inc., Healthcare stocks news, Stocks on the mo...
Source: SeekingAlpha
Date: August, 01 2018 17:03
Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program for Parkinson's Disease
Healthy volunteer study of DNL201 meets all objectives in phase 1 clinical study, including CSF exposure levels and LRRK2 inhibition, as well as pathway engagement, at doses that were safe and well tolerated DNL201 will advance to Phase 1b in Parkinson’s disease patients with an...
Source: GlobeNewswire
Date: August, 01 2018 16:30
Biogen slump pressures other biotechs
Biogen's ( BIIB -8.9% ) post-BAN2401 data-stoked drop appears to be affecting some of the other Alzheimer's players. More news on: Biogen Inc., SPDR Biotech ETF, Eisai Co., Ltd. ADR, Healthcare stocks news, Stocks on the move, News on ETFs, Read more ...
Source: SeekingAlpha
Date: July, 26 2018 10:32

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0819.3017.7319.5917.57644,544
2018-05-1718.8618.9919.1218.6638194,762

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1387,179309,67028.1522Cover
2018-12-1248,459135,75835.6951Short
2018-12-1140,07060,60166.1210Short
2018-12-1053,55289,31359.9599Short
2018-12-0748,30482,91658.2565Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DNLI.


About Denali Therapeutics Inc. (NASDAQ: DNLI)

Logo for Denali Therapeutics Inc. (NASDAQ: DNLI)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: DNLI)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 11 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 11 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 07 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 19 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 19 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 13 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 13 2018

       

       


      Daily Technical Chart for (NASDAQ: DNLI)

      Daily Technical Chart for (NASDAQ: DNLI)


      Stay tuned for daily updates and more on (NASDAQ: DNLI)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: DNLI)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DNLI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of DNLI and does not buy, sell, or trade any shares of DNLI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/